TITLE

UCB LICENSES SEPRACOR U.S. PATENTS FOR ANTIHISTAMINE

PUB. DATE
April 2006
SOURCE
Worldwide Biotech;Apr2006, Vol. 18 Issue 4, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the licensing agreement signed by UCB S.A. and Sepracor Inc. relating to the antihistamine levocetirizine. Terms of the agreement; Royalties earned by Sepracor from UCB; Remarks from Timothy J. Barberich, chairman and CEO of Sepracor, regarding the licensing agreement.
ACCESSION #
20374489

 

Related Articles

  • Immunomedics, UCB Rework Agreement for Lupus Drug. Powers, Marie // BioWorld Today;12/29/2011, Vol. 22 Issue 249, p1 

    The article reports on the revision of the development, collaboration and license agreement of Immunomedics Inc. and UCB SA. The agreement covers the exclusive rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications. Under the deal, UCB can choose a...

  • Immunomedics, UCB Rework Agreement for Lupus Drug. Powers, Marie // BioWorld International;1/4/2012, Vol. 17 Issue 1, p3 

    This article reports on the decision of Immunomedics Inc. and UCB SA to revise their development, collaboration and license agreement for the worldwide rights to develop, market and sell the former firm's epratuzumab for autoimmune diseases. The revised deal would allow UCB to select a partner...

  • Chalk One Up for Sepracor's Shorts. Kover, Amy // Fortune;6/21/1999, Vol. 139 Issue 12, p206 

    Reports on the collapse of Sepracor Inc. stock. Company attempts on licensing improved pharaceuticals; The shorting of outstanding shares by traders; Effect of failure to license product on company stock; Selling of holdings by three Sepracor board members; Confidence in the company's...

  • pharmaceuticals & fine chemicals.  // Chemical Week;9/20/2006, Vol. 168 Issue 31, p52 

    The article offers news related to the pharmaceutical and fine chemicals industries as of September 20, 2006. An agreement was signed by UCB for a research license to use a high-yield cell line for the efficient manufacture of monoclonal antibodies developed by biotech firm Crucell. A vaccines...

  • VICAL GRANTS OPTION LICENSE TO MERCK FOR CANCER TARGETS.  // Biotech Business;Oct2003, Vol. 16 Issue 10, p4 

    Announces that Vical Inc. and Merck & Co. have amended their existing license agreement.

  • Tech/Net Briefs.  // New Hampshire Business Review;12/13/2002, Vol. 24 Issue 26, p23B 

    Reports technological developments in New Hampshire as of December 2002. Investment of Canon U.S.A. in eCopy Inc.; Contract between SkillSoft Inc. and the Air Force Communications Agency; Licensing agreement between IBM Corp. and Nashua Corp.

  • Shrinkwrap & click-through accords under proposed UCC article 2B. Chamberlin, Carl W. // Electronic News;08/03/98, Vol. 44 Issue 2230, p8 

    Opinion. Comments on the provisions on `shrinkwrap' license agreements of the Uniform Commercial Code (UCC), a source of contract law in the United States. Inclusion of such agreements inside prepackaged software; Court rulings on shrinkwrap agreements; Mass market transactions under the UCC.

  • licenses granted & now available.  // License!;Feb2003, Vol. 6 Issue 1, p96 

    Presents a chart related to license agreements as of February 2003.

  • Appendix B: Licence and Service Agreement.  // Software Contracts -- Negotiating & Drafting Techniques for the ;1999, p213 

    Information about licence and service agreements is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics